Richard L. Cassin Publisher and Editor

Andy Spalding Senior Editor

Jessica Tillipman Senior Editor

Elizabeth K. Spahn Editor Emeritus

Cody Worthington Contributing Editor

Julie DiMauro Contributing Editor

Thomas Fox Contributing Editor

Marc Alain Bohn Contributing Editor

Bill Waite Contributing Editor

Shruti J. Shah Contributing Editor

Russell A. Stamets Contributing Editor

Richard Bistrong Contributing Editor 

Eric Carlson Contributing Editor

Bill Steinman Contributing Editor

Aarti Maharaj Contributing Editor

FCPA Blog Daily News

Entries in pharmaceutical companies (3)


Pharmas disclose FCPA-related investigations involving seven countries

Six pharmas have disclosed open FCPA-related investigations.

Click to read more ...


Corruption risk in pharma and medical device markets

At the 17th Annual Pharmaceutical and Medical Device Compliance Congress last month in Washington DC, Paul Hastings Partner Gary Giampetruzzi and FCPA Blog Contributing Editor Richard Bistrong exchanged perspectives on pharma compliance risks.

Click to read more ...


China's changing view of bribe givers

It has been typical under PRC law for bribe takers to be punished more severely than bribe givers. The policy was to punish extortion and incentivize cooperation with government investigations. But as recent investigations into the sales practices of big pharmaceutical companies have shown, this policy may be changing.

Click to read more ...